Skip to main content

Table 5 Summary of MRSS values by treatment

From: Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Treatment group n MRSS, mean (SD)
Day 1 Day 85 Change from day 1 to day 85
Placebo 4 22.8 (7.5) 25.0 (7.2) 2.3 (6.1)
MEDI-551 0.1 mg/kg 1 31.0 (NA) 17.0 (NA) -14.0 (NA)
MEDI-551 0.3 mg/ 4 23.5 (7.6) 17.3 (5.1) -6.3 (3.5)
MEDI-551 1.0 mg/kg 6 20.0 (9.8) 15.5 (8.7) -4.5 (1.5)
MEDI-551 3.0 mg/kg 6a 23.3 (12.8) 17.8 (13.1) -6.6 (3.0)
MEDI-551 10.0 mg/kg 7 24.0 (5.1) 20.4 (7.7) -3.6 (5.7)
Combined MEDI-551 24b 23.0 (8.7) 17.9 (8.5) -5.4 (4.2)
  1. MRSS modified Rodnan skin score
  2. aAt day 85, n = 5
  3. bAt day 85, n = 23
\